The therapeutic potential of targeting cyclin-dependent kinases, such as CDK4/6 and Cyclin D, has been recognized, and several inhibitors, such as palbociclib and ribociclib, have been approved for the treatment of lung cancer 14. This evidence concerns the gene CDK4 and lung carcinoma.